

Andrea Becciolini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2898740/publications.pdf>

Version: 2024-02-01

59
papers

1,157
citations

471061

17
h-index

414034

32
g-index

61
all docs

61
docs citations

61
times ranked

1989
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Pisotriquetral arthritis: "forgotten" joint in ultrasound imaging of the wrist. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e97-e97. | 0.5 | 4 |
| 2 | Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 621. | 1.0 | 9 |
| 3 | Adalimumab and ABP 501 in the Treatment of a Large Cohort of Patients with Inflammatory Arthritis: A Real Life Retrospective Analysis. <i>Journal of Personalized Medicine</i> , 2022, 12, 335. | 1.1 | 2 |
| 4 | Apremilast retention rate in clinical practice: observations from an Italian multi-center study. <i>Clinical Rheumatology</i> , 2022, 41, 3219-3225. | 1.0 | 3 |
| 5 | Imaging in the Assessment of Musculoskeletal Manifestations Associated with Inflammatory Bowel Disease. <i>Gastroenterology Insights</i> , 2021, 12, 100-110. | 0.7 | 2 |
| 6 | Mild cognitive impairment in psoriatic arthritis. <i>Medicine (United States)</i> , 2021, 100, e24833. | 0.4 | 9 |
| 7 | Cycling or swap biologics and small molecules in psoriatic arthritis. <i>Medicine (United States)</i> , 2021, 100, e25300. | 0.4 | 4 |
| 8 | Internal medicine inpatients' prevalence of misdiagnosed severe osteoporosis. <i>Osteoporosis International</i> , 2021, 32, 2361-2364. | 1.3 | 1 |
| 9 | bDMARDs retention rate in the biosimilar era: A real-life monocentric study. <i>European Journal of Rheumatology</i> , 2021, 8, 109-110. | 1.3 | 2 |
| 10 | Filgotinib as rheumatoid arthritis therapy. <i>Drugs of Today</i> , 2021, 57, 543. | 0.7 | 1 |
| 11 | A Parsonage-Turner Syndrome secondary to Parvovirus B19 infection. <i>Acta Biomedica</i> , 2021, 92, e2021129. | 0.2 | 0 |
| 12 | Home-based unsupervised pulmonary rehabilitation program improves the respiratory disability in systemic sclerosis patients with dyspnea: an observational prospective study. <i>Monaldi Archives for Chest Disease</i> , 2021, , . | 0.3 | 0 |
| 13 | Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort. <i>Rheumatology International</i> , 2020, 40, 263-272. | 1.5 | 10 |
| 14 | Comment on: Lower urinary tract symptoms in systemic sclerosis: a detailed investigation. <i>Rheumatology</i> , 2020, 59, 1455-1456. | 0.9 | 1 |
| 15 | Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 57-70. | 2.0 | 99 |
| 16 | Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects. <i>Drugs</i> , 2019, 79, 1741-1755. | 4.9 | 39 |
| 17 | Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 573-581. | 1.9 | 33 |
| 18 | SAT0375...MILD COGNITIVE IMPAIRMENT IN PSORIATIC ARTHRITIS: PREVALENCE AND ASSOCIATED FACTORS. , 2019, , . | | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | FRI0042â€¦CERTOLIZUMAB PEGOL EFFECTIVENESS IN WOMEN OF CHILDBEARING AGE WITH RHEUMATOID ARTHRITIS: RETROSPECTIVE ANALYSIS OF AN INTERNATIONAL MULTICENTRE COHORT. , 2019, , . | | 0 |
| 20 | SAT0414â€¦CLINICAL PRESENTATION OF PAGET DISEASE OF BONE: IS IT CHANGING? A RETROSPECTIVE ANALYSIS ON 368 PATIENTS. , 2019, , . | | 17 |
| 21 | Sex and Management of Rheumatoid Arthritis. <i>Clinical Reviews in Allergy and Immunology</i> , 2019, 56, 333-345. | 2.9 | 126 |
| 22 | Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. <i>Drugs in Context</i> , 2019, 8, 1-12. | 1.0 | 55 |
| 23 | Twoâ€¦year persistence of golimumab as secondâ€¦line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: realâ€¦life data from the <scp>LORHEN</scp> registry. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 422-430. | 0.9 | 22 |
| 24 | Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors. <i>Modern Rheumatology</i> , 2018, 28, 542-549. | 0.9 | 8 |
| 25 | The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future. <i>BioMed Research International</i> , 2018, 2018, 1-11. | 0.9 | 12 |
| 26 | The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts. <i>Autoimmunity Reviews</i> , 2018, 17, 1251-1258. | 2.5 | 2 |
| 27 | Sarilumab: patient-reported outcomes in rheumatoid arthritis. <i>Patient Related Outcome Measures</i> , 2018, Volume 9, 275-284. | 0.7 | 14 |
| 28 | The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 1421-1429. | 2.0 | 13 |
| 29 | Vitamin D and Spondyloarthritis: Review of the Literature. <i>Open Rheumatology Journal</i> , 2018, 12, 214-225. | 0.1 | 5 |
| 30 | Sonographic findings in a case of cactus thorn arthritis. <i>Journal of Clinical Ultrasound</i> , 2017, 45, 240-241. | 0.4 | 1 |
| 31 | The 12-item Psoriatic Arthritis Impact of Disease Questionnaire: Construct Validity, Reliability, and Interpretability in a Clinical Setting. <i>Journal of Rheumatology</i> , 2017, 44, 279-285. | 1.0 | 66 |
| 32 | Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences. <i>Clinical Rheumatology</i> , 2017, 36, 1747-1755. | 1.0 | 31 |
| 33 | Change Over Time in the Pattern of Clinical Response to First-line Biologic Drugs in Patients with Rheumatoid Arthritis: Observational Data in a Real-life Setting. <i>Journal of Rheumatology</i> , 2017, 44, 262-263. | 1.0 | 4 |
| 34 | Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 183-192. | 1.6 | 63 |
| 35 | The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives. <i>Autoimmunity Reviews</i> , 2017, 16, 1185-1195. | 2.5 | 67 |
| 36 | Eightâ€¦Year Retention Rate of Firstâ€¦Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis. <i>Arthritis Care and Research</i> , 2017, 69, 867-874. | 1.5 | 32 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | THU0365â€¦Do extra-articular manifestations affect the choice of biologic therapy in patients with axial spondyloarthritis? a multicentre real-life analysis. , 2017, , . | | 0 |
| 38 | A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability. Drug Design, Development and Therapy, 2017, Volume 11, 1969-1978. | 2.0 | 11 |
| 39 | Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date. Drug Design, Development and Therapy, 2017, Volume11, 211-223. | 2.0 | 17 |
| 40 | Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Design, Development and Therapy, 2017, Volume 11, 1593-1603. | 2.0 | 85 |
| 41 | Twelveâ€¢Year Retention Rate of Firstâ€¢Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Realâ€¢Life Data From a Local Registry. Arthritis Care and Research, 2016, 68, 432-439. | 1.5 | 69 |
| 42 | The Introduction of Etanercept Biosimilar In The Practice of A Tertiary Rheumatologic Centre In Italy: A Budget Impact Model. Value in Health, 2016, 19, A534. | 0.1 | 2 |
| 43 | The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry. Journal of International Medical Research, 2016, 44, 113-118. | 0.4 | 12 |
| 44 | Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2016, 45, 519-532. | 1.6 | 45 |
| 45 | FRI0497â€¦Drug Retention and Pattern of Discontinuation of the First-Line Anti-TNF Drug in a Large Cohort of Patients with Adult or Juvenile-Onset Inflammatory Arthritides. Annals of the Rheumatic Diseases, 2015, 74, 608.2-609. | 0.5 | 0 |
| 46 | FRI0111â€¦Change Over Time in the Pattern of Clinical Response to First-Line Biologic Drugs: Observational Data from a Local Registry. Annals of the Rheumatic Diseases, 2015, 74, 460.1-460. | 0.5 | 0 |
| 47 | Comment on: Intravenous neridronate in the treatment of acute painful knee osteoarthritis: a randomized controlled study: reply. Rheumatology, 2015, 54, 2117-2118. | 0.9 | 0 |
| 48 | Structural integrity versus radiographic progression in rheumatoid arthritis: FigureÂ¹. RMD Open, 2015, 1, e000064. | 1.8 | 10 |
| 49 | Intravenous neridronate in the treatment of acute painful knee osteoarthritis: a randomized controlled study. Rheumatology, 2015, 54, 1826-1832. | 0.9 | 50 |
| 50 | Is there a need for new thresholds to define remission and low disease activity by Disease Activity Score 28 calculated with C reactive protein? Real life data from a local registry. Annals of the Rheumatic Diseases, 2015, 74, e5-e5. | 0.5 | 11 |
| 51 | Clinical and serological features of juvenile systemic lupus erythematosus in an italian tertiary centre of pediatric rheumatology. Pediatric Rheumatology, 2014, 12, . | 0.9 | 1 |
| 52 | SAT0524â€¦Predictors of A Clinical Response to Bisphosphonates Treatment in Patients with Complex Regional Pain Syndrome Type I. Annals of the Rheumatic Diseases, 2014, 73, 781.1-781. | 0.5 | 0 |
| 53 | Bone erosions in rheumatoid arthritis: ultrasound findings in the early stage of the disease. Rheumatology, 2014, 53, 1100-1107. | 0.9 | 44 |
| 54 | THU0171â€¦Which Adverse Events (AES) of Biological Therapy (BT) Led to Discontinuation of Treatment in A Cohort of 377 JIA Patients in Comparison to 1115 Patients Affected by Ra, As, PSA in the Department of Rheumatology of G. Pini Institute. Annals of the Rheumatic Diseases, 2014, 73, 239.3-240. | 0.5 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | SAT0214â€¦Reliability and Validity of the Italian Version of the Ucla-Scleroderma Clinical Trial Consortium-Gastrointestinal Tract Instrument in Patients with Systemic Sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A653.1-A653. | 0.5 | 1 |
| 56 | SAT0413â€¦Inter-reader reliability in the assessment of nailfold capillary abnormalities: A pilot study about an intensive videocapillaroscopy training programme. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 611.3-612. | 0.5 | 0 |
| 57 | THU0432â€¦Bone erosions in rheumatoid arthritis: Ultrasound findings in the early stage of the disease. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 301.2-301. | 0.5 | 4 |
| 58 | Interreader Reliability in Assessment of Nailfold Capillary Abnormalities by Beginners: Pilot Study of an Intensive Videocapillaroscopy Training Program. <i>Journal of Rheumatology</i> , 2012, 39, 1248-1255. | 1.0 | 18 |
| 59 | Sonographic subclinical entheselial involvement in dialysis patients. <i>Clinical Rheumatology</i> , 2011, 30, 907-913. | 1.0 | 14 |